<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623904</url>
  </required_header>
  <id_info>
    <org_study_id>CRBMACS</org_study_id>
    <nct_id>NCT05623904</nct_id>
  </id_info>
  <brief_title>Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis</brief_title>
  <official_title>Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis: a Multicenter, Open, Randomized Controlled Trial in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Xinjiang Uygur Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety&#xD;
      of carotid artery stenting/carotid endarterectomy versus best medical treatment for&#xD;
      asymptomatic carotid artery stenosis in Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open, randomized controlled trial to evaluate the efficacy and safety&#xD;
      of carotid artery stenting/carotid endarterectomy versus best medical treatment for&#xD;
      asymptomatic carotid artery stenosis in Chinese population. The study will be conducted at 11&#xD;
      centers and is expected to enroll 1056 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any Periprocedural Stroke, Myocardial Infarction, or Death During1 month Peri-procedural Period, and Postprocedural Ipsilateral Stroke 1 to 12-months.</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Composite of any periprocedural stroke (ipsilateral or contralateral; major or minor), myocardial infarction, or death during1 month peri-procedural period, and postprocedural ipsilateral stroke 1 to 12-months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>1 day</time_frame>
    <description>Technical success was defined as final residual stenosis less than 30%, TIMI grade 3, and no dissection or thrombus after any endovascular treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of complications within 30 days, complications include：Cranial nerve and peripheral nerve injury, vascular injury, non cerebral hemorrhage, wound complications as neck incision or related to puncture site, and other (such as anesthesia) complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of myocardial infarction at 30 days follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ipsilateral stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of ipsilateral stroke at 30 days follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of death at 30 days follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid restenosis rate</measure>
    <time_frame>12 months</time_frame>
    <description>Carotid restenosis was defined as restenosis ≥50% after carotid revascularization, that is, peak systolic velocity ratio (PSVR) ≥2.0 on ultrasound examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion revascularization (TLR) is defined as the re-percutaneous intervention or bypass grafting of the target lesion for restenosis or other complications of the target lesion. All TLR should be preclassified as clinically drived or non-clinically drived before the investigator performs angiography again.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in cognitive function</measure>
    <time_frame>30 days</time_frame>
    <description>Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 30 days follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in cognitive function</measure>
    <time_frame>30 days</time_frame>
    <description>Cognitive function was assessed by Mini-mental State Examination (MMSE) at 30 days follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>Cognitive function was assessed by Montreal Cognitive Assessment Scale (MoCA) at 12 months follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>Cognitive function was assessed by Mini-mental State Examination (MMSE) at 12 months follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1056</enrollment>
  <condition>Carotid Artery Stenting</condition>
  <condition>Carotid Endarterectomy</condition>
  <condition>Best Medical Treatment</condition>
  <condition>Carotid Artery Stenosis Asymptomatic</condition>
  <arm_group>
    <arm_group_label>Carotid Revascularization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carotid Artery Stenting/Carotid endarterectomy + Best Medical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Medical Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid Revascularization</intervention_name>
    <description>Carotid Artery Stenting/Carotid Endarterectomy</description>
    <arm_group_label>Carotid Revascularization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Treatment</intervention_name>
    <description>Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP &lt; 140 mmHg, HDL &lt; 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.&#xD;
In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.</description>
    <arm_group_label>Carotid Revascularization</arm_group_label>
    <arm_group_label>Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 40-80 years;&#xD;
&#xD;
          2. Carotid artery stenosis 50%-90% (ultrasound, CT, or DSA);&#xD;
&#xD;
          3. Asymptomatic carotid stenosis, that is, no transient ischemic attack, stroke, or other&#xD;
             neurological symptoms in the past 6 months;&#xD;
&#xD;
          4. Patients who could complete 12 months of follow-up;&#xD;
&#xD;
          5. Patients who signed informed consent forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had a TIA, stroke, or other related neurological symptoms within the&#xD;
             previous 6 months;&#xD;
&#xD;
          2. Patients with spontaneous intracerebral hemorrhage in the past 12 months；&#xD;
&#xD;
          3. Patients with large intracranial aneurysms (diameter&gt; 5mm)，and cannot be treated in&#xD;
             advance or contemporaneous;&#xD;
&#xD;
          4. Chronic total occlusion without obvious cerebral ischemia symptoms；&#xD;
&#xD;
          5. Patients with neurologic disorder that caused transient or permanent neurological&#xD;
             deficits and can not be identified with transient ischemic attack or stroke；&#xD;
&#xD;
          6. Patients with severe dementia;&#xD;
&#xD;
          7. Common carotid artery opening lesion；&#xD;
&#xD;
          8. Severe intracranial stenosis in tandem;&#xD;
&#xD;
          9. Carotid artery dissection;&#xD;
&#xD;
         10. Carotid artery aneurysm;&#xD;
&#xD;
         11. Myocardial infarction occurred within 30 days；&#xD;
&#xD;
         12. It is known that two or more proximal or main coronary artery stenosis ≥70%, untreated&#xD;
             or unable to recanalize;&#xD;
&#xD;
         13. Ejection fraction &lt;30% or New York Heart Association (NYHA) functional class III or&#xD;
             higher；Unstable angina，ie angina at resting state and electrocardiogram changes；&#xD;
&#xD;
         14. Patients with cardiac emboli sources, such as left ventricular aneurysm, intraluminal&#xD;
             filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific&#xD;
             aortic stenosis, infective endocarditis, mitral stenosis, atrial septal defect, atrial&#xD;
             septal aneurysm, or left atrial myxoma；&#xD;
&#xD;
         15. Platelet count &lt;5×104/μL, INR&gt;1.5, Bleeding time &gt; 1 min, or heparin-related&#xD;
             thrombocytopenia；Patients contraindicated to heparin and antiplatelet drugs;&#xD;
&#xD;
         16. Patients with coagulation dysfunction.&#xD;
&#xD;
         17. Poor control of diabetes, fasting blood glucose &gt;22mmol/L and ketone body &gt; +2；&#xD;
&#xD;
         18. Malignant tumor or respiratory insufficiency, life expectancy &lt; 5 years.&#xD;
&#xD;
         19. Insufficiency of vital organs: forced expiratory volume at one second &lt; 30%&#xD;
             (predicted)； dialysis-dependent renal failure; intolerance to anesthesia;&#xD;
&#xD;
         20. Currently waiting main organ transplants (ie heart, lung, liver, kidney), or are doing&#xD;
             relevant evaluate；&#xD;
&#xD;
         21. Need to perform other general anesthesia surgery during the same period；&#xD;
&#xD;
         22. Pregnant or lactating women；&#xD;
&#xD;
         23. Those who participated in clinical trials of other drugs or medical devices before the&#xD;
             inclusion did not reach the end of the time limit；&#xD;
&#xD;
         24. Investigators consider the patient inappropriate to participate in this clinical&#xD;
             trial；&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongquan Gu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongquan Gu, Dr.</last_name>
    <phone>+8615901598209</phone>
    <email>gu15901598209@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xixiang Gao, Dr.</last_name>
    <phone>+8613581674309</phone>
    <email>vascsurgeon@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehong Zheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianrui Guo, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Xixiang Gao</last_name>
      <phone>+8613581674309</phone>
      <email>vascsurgeon@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100192</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Bi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050057</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonan Lv, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqiang Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianlin Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqing Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohu Ge</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>October 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>January 27, 2023</last_update_submitted>
  <last_update_submitted_qc>January 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carotid Revascularization</keyword>
  <keyword>Carotid Artery Stenting</keyword>
  <keyword>Carotid Endarterectomy</keyword>
  <keyword>Best Medical Treatment</keyword>
  <keyword>Carotid Artery Stenosis Asymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

